Viridian Therapeutics Common Stock Net 2014-2025 | VRDN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Viridian Therapeutics common stock net from 2014 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Viridian Therapeutics common stock net from 2014 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.1B
Amgen (AMGN)	$153.8B
Gilead Sciences (GILD)	$139.7B
Vertex Pharmaceuticals (VRTX)	$100.5B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$80.3B
CSL (CSLLY)	$66.8B
Regeneron Pharmaceuticals (REGN)	$61.4B
Alnylam Pharmaceuticals (ALNY)	$59.3B
Argenex SE (ARGX)	$43.1B
Insmed (INSM)	$28.5B
BioNTech SE (BNTX)	$24.5B
Royalty Pharma (RPRX)	$20.8B
Biogen (BIIB)	$19.4B
Genmab (GNMSF)	$16.4B
Incyte (INCY)	$16.3B
Genmab (GMAB)	$16.1B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B